Uncategorized

Ono Enters into Collaboration Agreement with EVQLV to Generate Novel Antibodies against Multiple Targets Utilizing EVQLV’s AI-powered Antibody Design Engine for Development of Innovative Antibody Drugs

Ono Pharmaceutical Co., Ltd. announced that it has entered into a discovery collaboration agreement with EVQLV, INC, to generate novel antibodies against multiple targets selected by Ono, for the development of innovative antibody drugs.

Ono Enters into Collaboration Agreement with EVQLV to Generate Novel Antibodies against Multiple Targets Utilizing EVQLV’s AI-powered Antibody Design Engine for Development of Innovative Antibody Drugs Read More »

Scroll to Top